Robert Leshner, a four-time founder and the CEO of Superstate, a fintech innovator bridging financial assets with crypto capital markets, talks with Orrick’s Albert Vanderlaan about the evolution of blockchain, the regulatory...more
Continued volatility in the equity capital markets has revived what was thought to be a zombie after 2022 – the SPAC. There is an old investment banking mantra that they can do an IPO in a down market or an up market, but not...more
Q1 2025 marked another strong quarter for life sciences VC financing, but the industry faces unique headwinds amid ongoing shake-ups in regulatory leadership and US trade relationships. Key takeaways for Q1 2025 include: •...more
On September 27, 2024, the SEC adopted new rules, called “EDGAR Next,” to enhance the security of the EDGAR system. Action to comply with EDGAR Next is required of every entity and individual that currently makes EDGAR...more
The SEC announced that companies can now submit registration statements for confidential review before public filing in connection with most registered offerings. This expansion builds on the confidential filing process that...more
3/6/2025
/ Capital Formation ,
Capital Markets ,
Disclosure Requirements ,
Filing Requirements ,
Financial Reporting ,
Initial Public Offering (IPO) ,
Publicly-Traded Companies ,
Registration Statement ,
Securities and Exchange Commission (SEC) ,
Securities Regulation ,
Special Purpose Acquisition Companies (SPACs)
Q4 2024 marked the conclusion of a turnaround year for life sciences venture investment. After two consecutive years of declining activity and macroeconomic uncertainty, the dust has settled, and investment is back on the...more
WHAT WE'RE SEEING -
In this Life Sciences & Healthtech edition of The Download, we take on key trends at the intersection of tech and healthcare, continuing the energizing conversation from JPM Healthcare last week. 01 A...more
Since the previous quarter’s Life Sciences Snapshot, robust dealmaking activity in Q3 has launched YTD life sciences VC deal activity to near parity with 2023 figures, firmly positioning 2024 as the year to break the two-year...more
The U.S. Court of Appeals for the Fifth Circuit vacated the SEC’s approval of Nasdaq’s board diversity rules. Consequently, Nasdaq-listed companies are no longer required to satisfy Nasdaq’s “comply or explain” director...more
I'm really excited to be here with you today for two reasons. One, we've never been in the same room together, so it’s awesome to finally be able to do that. But the second reason is that earlier this year, you and I had the...more
SEC officials have declared artificial intelligence (“AI”) “the most transformative technology of our times” while cautioning that “if a public company is using AI, that company has to be honest about the role AI plays in its...more
It’s never too early to prepare an exit strategy, whether that exit is through an M&A, IPO or additional private financing. Albert Vanderlaan, Justin Yi and Samir Bakhru discuss the need for good corporate hygiene, process...more
01 A conversation with Evercore on the market outlook
02 Will there be an alternative path to public?
03 What’s ahead for tech and life sciences IPOs?
04 The Download Quiz: Venture Capital Trends /
01A CONVERSATION WITH...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q2 2024 include: • Life sciences VC deal value reached $10.6 billion in Q2 2024, up more than 30% from Q1, which brings the...more
01 Do I need to make money to go public?02 A new M&A playbook in the age of AI03 Cyber enforcement forecast post-SolarWinds decision04 Cyber diligence for IPOs with Kroll’s CISO05 The Download Quiz: Venture capital trends...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q1 2024 include: • Life sciences VC deal value in Q1 totaled $7.8 billion, which represents a 22.1% increase in value from Q4...more
With the compliance deadline for the newly issued Item 408(b) of Regulation S-K approaching for calendar-year-end companies and the increased use by the Department of Justice and the SEC of data analytics in pursuing insider...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q4 2023 include: • Life sciences VC deal value in Q4 2023 totaled $6.6 billion, representing a 25.0% decrease from the prior...more
Many private companies have not kept up with recent changes affecting when certain disclosures or reports may be required. That consensus, along with other takeaways, emerged in recent panel discussions at the Society for...more
The Securities and Exchange Commission (the “SEC”) has finalized its long-awaited rules regarding special purpose acquisition companies (“SPAC”). So, what are the key aspects of these rules that SPAC market participants...more
On December 19, 2023, the Fifth Circuit officially vacated the SEC’s share repurchase disclosure rules. As a result of the Court’s decision, companies will not need to comply with the now-vacated share repurchase disclosure...more
On October 31, 2023, the Fifth Circuit ruled in Chamber of Commerce of the USA v. SEC that the SEC violated the Administrative Procedure Act when it adopted enhanced share repurchase disclosure rules. The Court provided the...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q3 2023 include:
Life sciences VC deal value in Q3 2023 totaled $7.7 billion, representing an uptick from last quarter...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q2 2023 include:
• Life sciences VC deal value in Q2 2023 totaled $6.7 billion across 384 deals, representing a slight...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q1 2023 include:
• Life sciences VC deal value totaled $5.0 billion across 364 deals, representing a 40.9% decline in value...more